Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/21/2025 | $64.00 | Buy | Truist |
| 6/11/2025 | $76.00 | Outperform | Raymond James |
| 4/21/2025 | $51.00 | Outperform | Mizuho |
| 11/20/2024 | $65.00 | Outperform | Raymond James |
| 8/22/2024 | $55.00 | Overweight | Wells Fargo |
| 6/26/2024 | Overweight | Piper Sandler | |
| 6/24/2024 | Buy | TD Cowen |
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in three upcoming investor conferences taking place in September 2025. 2025 Wells Fargo Healthcare Conference Date:September 3, 2025Location:Boston, MAFormat:Investor Meetings Cantor Global Healthcare Conference Date:September 4, 2025Time:2:10 PM EDTLocation:New York, NYFormat:Fireside ChatPresenters:Daniel Lochner, Chief F
TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45's safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ("PH-ILD", Group 3 PH) to expand the therapeutic breadth of TX45 Complete results from Part A of the TX45 Phase 1b clinical trial presented at ESC Heart Failure 2025 confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in subjects with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF")Part B of the TX45 Phase 1b clinical trial in subjects with Group 2 Pulmonary Hypertension in Heart Failure with r
WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that it has been added to the broad-market Russell 3000® Index. Tectonic's addition follows the conclusion of the 2025 Russell US Indexes annual reconstitution and is effective after the open of US equity markets on Monday, June 30, 2025. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization.
8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
10-Q - Tectonic Therapeutic, Inc. (0001681087) (Filer)
EFFECT - Tectonic Therapeutic, Inc. (0001681087) (Filer)
SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel
Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan
TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech
Truist initiated coverage of Tectonic Therapeutic with a rating of Buy and set a new price target of $64.00
Raymond James resumed coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $76.00
Mizuho initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $51.00
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)